Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience.
Artur LemińskiKrystian KaczmarekTomasz ByrskiMarcin SłojewskiPublished in: PloS one (2021)
Our study implies that neoadjuvant chemotherapy with subsequent radical cystectomy provides significant improvement over upfront surgery in locoregional control and long-term prognosis of muscle-invasive bladder cancer. The urologic community should strive to maximize utilization of neoadjuvant chemotherapy, yet further research, including randomized control trials, is needed to validate superiority of dose-dense MVAC as the preferred regimen for cisplatin-eligible patients.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- lymph node
- sentinel lymph node
- muscle invasive bladder cancer
- end stage renal disease
- ejection fraction
- newly diagnosed
- rectal cancer
- minimally invasive
- healthcare
- peritoneal dialysis
- mental health
- prognostic factors
- squamous cell carcinoma
- open label
- radiation therapy
- double blind
- coronary artery bypass
- randomized controlled trial
- clinical trial
- placebo controlled
- patient reported outcomes
- percutaneous coronary intervention
- early stage
- surgical site infection
- anti inflammatory